W Health Ventures Unveils $70 Million Fund to Incubate Next-Gen Healthcare Startups in India and the US
W Health Ventures, a Boston and India-based healthcare venture capital firm launched by serial entrepreneur and philanthropist Sunil Wadhwani, has officially announced the launch of its second fund with a target corpus of $70 million (approximately ₹609–610 crore), and flexibility to raise an additional $30 million (hard cap) if that demand exists.
While traditional seed stage funds back dozens and dozens of early startups, which means limited operational involvement, Fund II is going to have a focused approach and will back eight to 10 companies over the next four years with a deep, hands-on incubation model. Managing Partner Dr. Pankaj Jethwani, indicated that the firm will back two companies every year with a great deal of operational support that far exceeds deploying passive capital.
A Deliberate Company Creation Model
W Health Ventures embraces a “company creation” thesis—internally incubating ideas, validating them rigorously, and then bringing in external founders to scale them. This approach builds on their first fund, but now with more capital and broader ambition. Jethwani emphasizes, “Fund II really doubles down on our company creation model… it’s something we’ve built through years of trial and error.”
Having deployed approximately $43 million across 12 companies in Fund I—including BeatO, Mylo, BabyMD, Wysa, and Nivaan—the firm continues to highlight that its portfolio companies have cumulatively served over 25 million patients globally.
Investment Thesis: India Plus Cross Border Growth
Fund II will retain W Health’s twofold investment strategy. It will first create single specialty care delivery platforms in India, filling clinical “white spaces” where existing healthcare infrastructure is still scarce. Second, it will expand AI enabled B2B healthcare services, specifically for U.S. healthcare systems, tapping into India’s robust engineering and clinical capabilities. As Dr. Jethwani described briefly, “Healthcare innovation in India is 10–15 years behind global standards. That gap is a generational opportunity.”
Cheque Size and Funding Strategy
Given the level of operational involvement planned, the firm’s capital allocation strategy shifts toward larger bets. Initial checks are expected in the $3–5 million range, with follow on rounds raising the total investment to $5–10 million per company over time. The Fund may reach $100 million if the oversubscription option is exercised by interested limited partners.
Sector Focus: Specialty Care & AI Services
Fund II will focus investment in areas where patient need is high and innovation lagging, such as oncology, psychiatry, geriatric care, longevity, and preventive health. These are sectors where W Health sees pressing patient challenges and ample room for transformative innovation.
Early Deployments from Fund II
W Health has already made two investments from Fund II. The first is EverHope Oncology, a clinical delivery platform incubated jointly with Narayana Health. With a $10 million day one investment, EverHope aims to standardize and improve cancer care delivery across India—covering chemotherapy, advanced diagnostics, surgical oncology, and ongoing supportive care in modern, patient centric centres nearer to homes
The second is a psychiatry focused, cross border managed services platform, currently operating in stealth mode. Backing U.S. psychiatry clinics, this model combines offshore clinical and revenue operations, practice management, and outcome tracking in an AI enabled framework.
Operational Edge & Team Expansion
To support its deeper operational model, W Health will soon recruit four senior operating partners, bringing expertise in offline healthcare delivery, AI enabled health services, and U.S. go to market strategy. This expanded team will bolster the firm’s ability to co-build ventures from conception through scale.
Macro Tailwinds and Market Opportunity
Healthcare in India continues to grow at 15–20% per annum, driven by rising affordability and increased private healthcare consumption. Even with this growth, India’s healthcare spend per capita remains just $1–2, whereas the U.S. averages $100, highlighting the immense long term opportunity With investors showing renewed interest in healthcare despite a broader slowdown in early stage funding—from $4 billion in 2023 to $3 billion in 2024—W Health’s Fund II launch stands in sharp contrast and signals confidence in its thesis and execution model.
Strategic Positioning: Beyond Healthtech
Consistently, W Health positions itself not merely as a healthtech investor but as a healthcare fund. While AI and digital tools power the firm’s ventures, Jethwani emphasizes that many healthcare challenges require offline, clinically integrated solutions—such as oncology and chronic care delivery that blend physical infrastructure with digital enablement.
With Fund II now officially launched and early deployments underway, W Health Ventures is doubling down on its unique blend of capital, operational rigor, and domain expertise. Its concentrated, company-creation strategy poised to back deep healthcare ventures aligned to both domestic and cross-border markets firmly position the firm to build companies—not just invest in them—and to reshape patient care for millions across India and beyond.
https://www.whealthventures.com/
#whealthventures#DigitalHealthBoom#FutureOfHealthcare#HealthTechFunding
#printpublication#modernstartupindia
